Current drug therapy has not been shown to modify the natural history of the disease, and its use is primarily directed at the prevention of thrombosis, guided by thrombosis risk models that are based on thrombosis history, age, and presence of JAK2 mutation [13, 14]. The gene discussed is JAK2; the disease is Venous thrombosis.